Premium Call Girls Cottonpet Whatsapp 7001035870 Independent Escort Service
VMRC
1. VENUS MEDICINE
RESEARCH CENTRE
Doing What We Know Best….
Venus Medicine Research Center
H.P, INDIA 04/05/12
2. Anti Microbial Resistance
VENUS MEDICINE
Oncology Drug Delivery
RESEARCH CENTRE
Wound and Skin Care Therapy
Translational Medicinal Approach
RESEARCH SPECIALIZATION 04/05/12
3. DEVELOPMENT OF NOVEL ANTIBIOTIC COMBINATIONS TO
CATER GROWING BACTRIAL RESISTANCE
VENUS MEDICINE
TARGET BASED ONCOLOGY DRUG DELIVERY
RESEARCH CENTRE
DEVELOPMENT OF SUSTAINED RELEASE INJECTIONS
SAFETY & TOXICOLOGICAL RESEARCH
DEVELOPING DIAGNOSTIC DEVICES FOR EARLY DETECTION
NOVEL DRUG DELIVERY SYSTEM BASED NATURAL
PRODUCTS
DEVELOPMENT
FOCUS AREAS 04/05/12
4. Local, National, Global problem
NO ACTION TODAY NO CURE TOMORROW RATIONAL TRANSLATIONAL PARADIGMS
INTEGRATED PROGRAMME FOR
ANTIMICROBIAL RESISTANCE BY VMRC
5. Inappropriate and Irrational Use of Medicines
when patients do not take the full course of a prescribed antibiotic
when poor quality antibiotics are used
when antibiotics are prescribed, but are not strictly needed
Underlying factors that drive drug resistance include:
• Inadequate national commitment to a comprehensive and coordinated response, ill-
defined
accountability, and insufficient engagement of communities.
• Weak or absent surveillance and monitoring systems.
• Inadequate systems to ensure quality and uninterrupted supply of medicines.
• Inappropriate and irrational use of medicines, including in animal husbandry.
• Poor infection prevention and control practices.
• Depleted medicines and vaccines, as well as insufficient research and
development on new products.
DRUG RESISTANCE DRIVERS
Emergence & Spread of Resistant Microorganisms
6. • Adjuvant Based Multi component Anti-infective Strategy
- Disrupt the resistance causing mechanisms in the microorganism
– Inducing Negative Adaptation
• Novel Antibiotic – Non-antibiotic Combination Strategy
• Chemical Vector Mediated Compatibility (CVMC) Technology
• Hospital Based Sentinel Surveillance System For Monitoring
antibiotic resistance in Nosocomial Infections (Molecular Epidemiology)
• Conducted at Central Institutions through out the country
• Established a repository of resistance strains representative of the region for research
VENUS APPROACH OF TACKLING
RESISTANCE
7. DRYING ANTIBIOTIC PIPELINES
Less than five per cent of products in research and development pipeline are antibiotic drugs
(Jabes D, The antibiotic R&D pipeline: an update, Curr Opin Microbiol. 2011 Oct;14(5):564-9. Epub 2011 Aug 26)
NEED TO THINK BEYOND ANTIBIOTICS
8. CSE1034: CVAE1020:
Designed to cater Designed to
ESBL producing cater
G-ve strains & MRSA, VRSA
MRSA
&V
Penem resistance NDM-1ENUS & VRE
MEDICINE
RESEARCH CENTRE
KEY
ACHIEVEMENTS
ESBL IN AMR NDM-1
CAA1020: Designed
CSE1034: to cater
Designed to Penem Aminoglycoside
cater NDM-1 Resistance & Quinolone
Resistant strains
04/05/12
9. 1. ESBL including Metalobetalactamases, Carbapenamases, NDM1 &
others
(In Late Clinical Validation and Marketed)
1. Efflux Pump Inhibitor
(In Late Clinical Validation and Marketed)
1. Biofilm Prevention and Destruction
(In Late Clinical Validation and Marketed)
1. Prevention of Conjugation al Plasmid Transfer
(In Late Clinical Validation and Marketed)
1. MRSA, VRSA, VRE
(In Late Clinical Validation and Marketed)
1. Fluoroquinolone Resistance
(In Late Clinical Validation and Marketed)
1. Quorum Sensing Inhibitors
(In Early Development Research)
HIGHLIGHTS OF TARGETED MECHANISMS
Small Molecule Research
10. VRP-1034 (Non-Antibiotic Adjuvant):
• Acts as a catalyst and provide synergy to the antibiotic
combinations
• Inhibits Efflux pump
• Alters Selective OMP(Outer membrane protein) expression
• Prevents Conjugal Transfer of Plasmids
• Prevents Resistance Development & Spread of Resistance
• Synergistically Breaks Biofilm & Prevents Biofilm development
• Decrease infection induced Hepato toxicity by its Anti oxidant
effect
• Potentially Neutralizes C.difficile Toxin
CSE1034 : A NOVEL ANTIBIOTIC –NON
ANTIBIOTIC ADJUVANT (VRP1034) ANTI-
INFECTIVE STRATEGY
Integrated Program for Antimicrobial Resistance: Highlights – CSE1034
11. 1.Strong Novel Products Pipeline for
A. Antimicrobial Resistance
B. Oncology targeted drug delivery
D.VENUS MEDICINE
C. Parenteral NDDS products
Neuro protection
RESEARCH early detection
E. Diagnostic agents for CENTRE
G. NDDS based Natural Products
2. DSIR, Govt of India approved center
3. 15 research products under patent protection
4. 341 patent application world wide: 84 granted
5. Trained and dedicated team of 100 experts
6. Strong regulatory team
7. GLP compliance in true spirit
VMRC STRENGTHS 04/05/12
14. Success Drivers »Targeting Unmet needs
FOCUSSED
»Combating Antimicrobial
resistance
APPROACH
»Exploring causes of
SKILLED MAN POWER therapeutic failures
WORLD CLASS
»Innovative Solutions for
incurable diseases
INFRASTRUCTURE
» Targeted drug delivery
HUGE IP WEALTH » Early diagnosis of critical diseases
CREATION
» Products with improved safety
INDUSTRY ACADEMIC profile
COLLABORATIONS » Products that have significant
increase in patient compliance
INDUSTRY -
» Ensuring world wide technology
INDUSTRY protection
COLLABORATIONS
15. Successfully Completed Phase I & Phase II Studies for a Novel
Cancer Detection Molecule, Started Phase III
Phase III Clinical Trials Completed for An Anti infective NCE
VENUS MEDICINE
Established & Launched Formulations for Super bugs like NDM-1
RESEARCH CENTRE
Validated An Early Typhoid Detection Probe
Platform Technology of Triple Conjugate for Selective Tumor
Targeting
Developed Wide spectrum Herbal Anti septic & Wound Cleanser
Launched Nano Technology Based Anti Arthritic Drug
Received Patent from US, Japan & Australia for MRSA, Quinolone
Resistant and MBL Resistant Therapy
EU CTD filed for Unique Patent Protected Antimicrobial Drug
Having Potential to Stop Spread & Treat Bacterial Resistance
RECENT MILESTONES 04/05/12
16. 1. CSE1034 : Caters to ESBL, NMD-1, Penem Resistance
2. CVAE1020 : Caters to MRSA, VRSA & VRE
3. CAA1020 : Caters to HAP, Febrile Neutropenia
4. CTE1046 : Developed for Cystic fibrosis
5. VRP004 VENUS MEDICINE
: For ICP Reduction & Preventing Neuronal Damage
6. P004 : For Mixed Aerobic & Anaerobic GI &GE Infections
7. VRP006RESEARCH CENTRE
: For Chronic Non Healing Wounds & Prevention of
Amputation in Diabetic Foot Ulcer
8. VRC001 : Controlled Release Anti-Inflammatory Analgesic
9. P001 : VAP Infections
10. P002 : For Pseudomonas Infections In Burns
11. P003 : For Gynecological Infections
12. VRP1008 : Nano Emulsion for Arthritis & Related Disorders
13. VRP1006 : Herbal Anti septic & Wound Cleanser
VMRC Introduced 13 Novel Patent
Protected Products in World Market 04/05/12
17. Molecular Animal House+ Four Zones
Cell Culture Stability
Biology Pre clinical
Studies
AREAS OF OPERATION
CPSCEA Approved Animal House 04/05/12
18. VENUS MEDICINE
RESEARCH CENTRE
Analytical Microbiology Natural Product
Chemical Division Division
Analysis
AREAS OF OPERATION:
GLP COMPLIANT
(Accreditation In Process) 04/05/12
19. VENUS ONCOLOGY PRODUCT
LYOPHILISED MEDICINE
RESEARCH CENTRE
DRY POWDER ANTIBIOTICS
INJ. IN AMPOULES
INJ. IN VIALS & BOTTLES
POLYMER BASED FORMULATIONS
TARGET DELIVERY SYSTEMS
INFRASTRUCTURE
6 Pilot Facilities +11 High Tech Labs04/05/12
20. VENUS MEDICINE
RESEARCH CENTRE
INTELLECTUAL SCIENTIFIC
DIVISION:
Trained & Dedicated Team of 70 Scientists 04/05/12
21. University of Illinois, Chicago, US
Institute of Microbial Technology (IMTECH), Chandigarh,
India
VENUS MEDICINE
Deptt of Microbiology,Punjab University, Chandigarh, India
RESEARCH CENTRE
National Institute of Pharmaceutical Education and Research
(NIPER), India
►Guru Jambeshwar University of Science and
Technology, Hissar, India
►King George Medical College, Lucknow, India
►Annamalai University,Tamil Nadu, India
►Amity University UP, India
RESEARCH COLLABORATIONS
Agreements/MOU with few institutes of national and international repute
04/05/12
has been entered into,for joint research and technical collaborations
22. VENUS MEDICINE
RESEARCH CENTRE
1.Best Innovation Award: 2010
2. Best Innovation Award: 2011
3. Patent Award from Pharmexcil:
Gold Category
4. Product of The Year 2012: Achnil
By Bio Spectrum Asia
RECOGNITIONS 04/05/12
23. Up to 10
PATENT 1
JAPAN
GRANT 2
KOREAN
STATUS 2 MEXICAN
84 out of 341 3US & 2 CANADA
2 RUSSIAN
3 INDIAN
3 UKRAINIAN
6 Each AUSTRALIA & NZ
8 SOUTH AFRICAN
47 EUROPEAN PATENTS
24. S.NO NAME QUALIFICATION EXPERIENCE
1 Dr Manu Chaudhary MSc, PhD Gentics, DBA(US) 22 years
2 Dr Pankaj A MBBS, MD (US) 8 years
Mandale
3 Dr Raj Kumar MSc, PhD Chemistry 10 years
4 Dr Vijay Naithani MSc, PhD Pharmacogonsy 12 years
5 Dr Anurag Payasi MSc, PhD, Post Doc Molecular Biology 11 years
6 Dr V Krishna Raju MSc, MD, Ph.D 8 years
7 Dr Vivek Dwivedi MSc, PhD Biochemistry 8 years
8 Dr Dhanya Nair MVSC 2 years
9 Dr Namrata Sharma MVSC Vet Pathology 1.5 years
10 Dr Keshav Naidu MSc, PhD Microbiology 5 years
11 Dr Vijay Kumar AE MMBS, MD Pharmacology 6 months
12 Mr Anuj Bhatnagar MSc Chemistry 7 years
13 Mr Anil Singh MSc Chemistry 8 years
14 Dr Arvind Singh MSc, PhD Microbiology 5 years
KNOWLEDGE POOL OF VMRC
25. •115 Internship Trainings Imparted to the Students from
Various Universities
• 86 M.Pharm Students: 180 days each
• 15 M.Sc /B.Pharm Trainees
• 14 M.Pharm + MTech Biotechnology in progress
•1 M.Phil : Degree of an Associated Team Member in
Collaboration with TDLU.
•1 Ph.D : Degree of an Associated Team Member in Collaboration
with Jhansi University.
• 2 Ph.D : In Progress
CREATING TALENT POOL
26. VENUS MEDICINE
RESEARCH CENTRE
INCREASING CONTRIBUTION OF
R&D PRODUCTS IN SALES 04/05/12
The Rise from 4% to 35% within five years in total sales
27. VENUS MEDICINE
RESEARCH CENTRE
PERCENT R&D EXPENDITURE
04/05/12
A continuous investment in R&D establishes the commitment
